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a b s t r a c t
Epstein Barr Virus (EBV) is a human tumor virus that is causally linked to malignancies such as Burkitt's
lymphoma, and gastric and nasopharyngeal carcinomas. Tethering of EBV genomes to cellular chromo-
somes is required for the synthesis and persistence of viral plasmids in tumor cells. However, it is not
established how EBV genomes are tethered to cellular chromosomes. We test the hypothesis that the
viral protein EBNA1 tethers EBV genomes to chromosomes speciﬁcally through its N-terminal AT-hook
DNA-binding domains by using a small molecule, netropsin, that has been shown to inhibit the AT-hook
DNA-binding of EBNA1 in vitro. We show that netropsin forces the loss of EBV genomes from epithelial
and lymphoid cells in an AT-hook dependent manner and that EBV-positive lymphoma cells are
signiﬁcantly more inhibited in their growth by netropsin than are corresponding EBV-negative cells.
& 2015 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Introduction
Epstein Barr Virus (EBV) is a ubiquitous human pathogen
associated with infectious mononucleosis and causally linked to
several human malignancies (for a review see Sugden (2014)).
There are close to 200,000 new cases of EBV-associated cancers
worldwide every year, including Burkitt's lymphoma, which is
among the most common childhood cancers in sub-Saharan Africa
(Cohen et al., 2011).
In EBV-derived tumor cells the virus exists in a latent state of
infection. Viral genomes are maintained as circular, extrachromosomal
plasmids, which are replicated in a licensed manner during the S-
phase of the cell cycle and subsequently segregated to daughter cells
equally and non-randomly during mitosis (Adams, 1987; Yates and
Guan,1991; Nanbo et al., 2007). In addition to cellular factors, only two
viral elements are necessary for the maintenance of EBV plasmids in
latently infected cells: a portion of the EBV genome called oriP and the
protein EBNA1 (Yates et al., 1984, 1985; Lupton and Levine, 1985). OriP
consists of two sets of repeated EBNA1 binding sites, DS (Dyad
Symmetry), which functions as an EBNA1-dependent replication
origin (Gahn and Schildkraut, 1989; Schepers et al., 2001) and FR
(Family of Repeats), which has been shown to be necessary for the
persistence of EBV and EBV-derived plasmids in latently infected cells
(Kanda et al., 2001).
EBNA1 is a homo-dimeric, multi-functional DNA-binding pro-
tein. It can site-speciﬁcally bind to sequences in EBV genomes
(Ambinder et al., 1990; Frappier and O’Donnell, 1991) and cellular
chromosomes (Dresang et al., 2009; Canaan et al., 2009; Lu et al.,
2010) through a C-terminal DNA-Binding and Dimerization
domain (DBD). EBNA1 also contains two N-terminal domains
called Linking Region 1 (LR1; aa 33–89) and Linking Region 2
(LR2; aa 325–376), which have been shown to be able to bind
mitotic chromosomes in cells and AT-rich DNA and G-quadruplex
RNA structures in vitro (Marechal et al., 1999; Sears et al., 2004a;
Norseen et al., 2009).
The replication and partitioning of EBV genomes and EBV-
derived plasmids requires them to be tethered to cellular chromo-
somes (Kanda et al., 2001; Holdin et al., 2013). Evidence indicates
that EBNA1 facilitates the association of EBV genomes to cellular
chromosomes by binding multiple sites in the FR portion of oriP
through its C-terminal DBD and tethering the viral plasmids to
cellular DNA through N-terminal domains (for a review see
Frappier (2012) and Lindner and Sugden (2007)). Although it
remains unclear exactly how LR1 and LR2 interact with cellular
DNA when EBNA1 is bound to FR through the C-terminal DBDs at
least three non-exclusive mechanisms have been suggested.
1) The cellular protein EBP2 has been proposed to mediate EBNA1's
association with chromosomes to facilitate the tethering of EBV
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genomes to cellular DNA (Shire et al., 1999; Kapoor et al., 2005). A
version of EBNA1 with LR2 deleted, ΔLR2-EBNA1, did not bind
EBP2 and cells expressing ΔLR2-EBNA1 could not maintain EBV-
derived plasmids as efﬁciently as cells expressing wtEBNA1 (Shire
et al., 1999). Also, depletion of EBP2 from cells led to a shift of EBV-
derived plasmids from the chromosomal to the soluble fraction of
cell lysates (Kapoor et al., 2005). However, other research has
shown the presence of LR1 alone is enough to localize EBNA1 to
mitotic chromosomes, and the failure of ΔLR2-EBNA1to support
EBV-derived plasmid maintenance could be complemented by
expressing versions of ΔLR2-EBNA1 containing multiple repeats
of LR1 (Sears et al., 2004a). In addition, while EBP2 and EBNA1
appeared to colocalize in interphase cells, there are contradictory
ﬁndings as towhether and when they do so duringmitosis (Nayyar
et al., 2009; Jourdan et al., 2012). Ultimately it remains unclear
what role EBP2 plays in the tethering of EBV genomes to cellular
chromosomes and the maintenance of viral DNAs in latently
infected cells, although recent hypotheses postulate that EBP2
stabilizes EBNA1-chromatin interactions during mitosis (Frappier,
2012).
2) LR1 and LR2 have been shown to bind G-rich RNA that is predicted
to form G-quadruplex structures (Norseen et al., 2009). A G-
quadruplex-interacting compound inhibited the association of
EBNA1 with mitotic chromosomes and EBNA1-dependent replica-
tion at oriP. In addition, culturing EBV-positive cells in the presence
of a G-quadruplex interacting compound reduced the genome
copy number and inhibited the growth of those cells (Norseen
et al., 2009). However, the ability of LR1 and LR2 to interact with
G-rich RNA has also shown to be important for the recruitment of
the origin recognition complex (ORC) at the DS portion of OriP
(Norseen et al., 2008). Thus it is unclear whether the reduction in
EBV genome copy number in the presence of G-quadruplex-
interacting compounds is due to inhibition of EBNA1's ability to
bind chromosomes and/or a reduction in EBNA1-ORC interactions.
3) EBNA1's LR1 and LR2 contain AT-hook DNA-binding domains
and are able to bind speciﬁcally to AT-rich DNA in vitro (Sears
et al., 2004a). In addition, the entire N-terminal half of EBNA1
can be replaced by cellular proteins that contain AT-hook DNA-
binding domains, such as HMGA1, and the fusion protein is able
to mediate persistence of EBV-derived plasmids in cells (Sears
et al., 2004b). However, other cellular and viral proteins that
bind chromosomes, but lack AT-hook DNA-binding domains,
such as the cellular protein Histone H1 or the ﬁrst 22 amino
acids of the LANA1 protein from Kaposi's Sarcoma-associated
Herpes Virus (KSHV) are also able to complement the loss of
EBNA1's LR1 and LR2 to maintain oriP replicons (Holdin et al.,
2013; Hung et al., 2001).
Because LR1 and/or LR2 are involved in all the proposed mechan-
isms by which EBNA1 tethers EBV genomes to cellular DNA it has been
challenging to test speciﬁcally whether EBNA1's ability to bind AT-rich
DNA is necessary in vivo for it to be able to maintain EBV genomes in
cells. We hypothesized that we could use small molecules that bind
speciﬁcally to AT-rich DNA and have been shown to disrupt the DNA-
binding of EBNA1 LR1 and LR2 in vitro (Sears et al., 2004a) to
determine whether the AT-hook activity of EBNA1 is necessary
in vivo for the maintenance of EBV genomes in latently infected cells.
These small molecules are not expected to disrupt the ability of EBNA1
to bind EBP2 or G-quadruplex RNA since they interact with AT-rich
DNA and not EBNA1 itself.
We used netropsin, which is a naturally-derived small molecule
that binds to the minor groove of AT-rich DNA (reviewed by Bailly
and Chaires, 1999). We reasoned that small molecules that bind
AT-rich DNA and inhibit EBNA1's binding to AT-rich DNA in vitro
would also inhibit its binding AT-rich DNA in vivo. If the AT-hook
domains of EBNA1 are responsible for tethering viral genomes to
chromosomes in latently infected cells, their inhibition by netrop-
sin would lead to a loss of EBV genomes from these cells.
We have extended previous in vitro results to show that inhibition
of EBNA1's AT-Hook functions by netropsin leads to a loss of EBV
genomes from several different cell lines, including tumor cells, in an
AT-hook dependent manner. In addition, culturing tumor cells depen-
dent on EBV in the presence of netropsin inhibits their growth
signiﬁcantly more than that of EBV-negative tumor cells.
Our results highlight a vital and necessary role for the AT-hook
binding ability of EBNA1's LR1 and LR2 in the maintenance of EBV
genomes in latently infected cells, such as tumor cells.
Methods
Cell lines and culture conditions
The Wp-restricted BL cell lines OkuI (Kelly et al., 2002) and SalI
(Kelly et al., 2002) expressing Bcl-XL and the PEL cell lines JSC-1
(Cannon et al., 2000) and BC-1 (Cesarman et al., 1995) were
cultured in RPMI 1640 (Invitrogen) supplemented with L-gluta-
mine, 10% fetal bovine serum (FBS), and antibiotics (200 U/mL
penicillin and 200 μg/mL streptomycin). HEK293 (Graham et al.,
1977) cells were cultured in Dulbecco's modiﬁed Eagle's medium
(Invitrogen) supplemented with L-glutamine, 10% FBS and anti-
biotics (D10F). HEK293 cells harboring p2089, p294-wtEBNA1,
p4880-H1 or p4881-LANA1 were grown in D10F and 400 μg/mL
hygromycin. HEK293 cells expressing EBNA1 were obtained from
the ATCC (CRL-10852) and grown in D10F with 250 μg/mL G418.
All cells were incubated in 5% CO2 at 37 1C.
Reagents
Netropsin dihydrochloride was purchased from either Sigma-
Aldrich (N9653-5 MG) or Enzo Life Sciences (ALX-380-088-M005).
Recombinant DNA plasmids
p2089, the recombinant B95.8 EBV genome with eGFP and
hygromycin resistance gene added, has been previously described
(Delecluse et al., 1998). p294 has also been described previously as
CMVpEBNA1 (Sugden and Warren, 1989). To generate plasmids
encoding EBNA1-DBD fused to either Histone H1 or the ﬁrst 22
amino acids of KSHV LANA1 we ﬁrst generated p294-NoEBNA1 by
digesting p294 with MfeI and XbaI (NEB). DNA oligonucleotides
encoding the Histone H1 protein, the ﬁrst 22 amino acids of KSHV
LANA1 or the C-terminal domain (aa 376–641) of EBNA1 were
ordered as Geneblocks (IDT DNA). These geneblocks were sub-
cloned into the p294-NoEBNA1 using the GIBSON Assembly
Cloning Kit (New England BioLabs) according to manufacturer's
instruction. The ﬁnal assemblies were veriﬁed by sequencing.
Transfections
293 cells were plated in 60-mm dishes and grown to 80%
conﬂuence. For each dish, 10 μg of vector and 1ug of reporter
plasmid was diluted in 250 μl of Opti-MEM (Invitrogen) and then
combined with pre-diluted Lipofectamine-Opti-MEM (Invitrogen)
mixture (8 μl of Lipofectamine diluted in 250 μl of Opti-MEM,
incubated 5 min at room temperature). DNA-Lipofectamine com-
plexes were incubated for 25 min at room temperature. Cells were
washed once with PBS and plated with 1.5 mL DMEM. The 500 μl
transfection mixture was added and the plates incubated for 4 h at
37 1C at 5% CO2. Following the incubation, the medium was
replaced with 5 mL of fresh D10F. The transfection efﬁciency was
determined 48 h later by counting GFP-positive cells.
A. Chakravorty, B. Sugden / Virology 484 (2015) 251–258252
Growth curve analysis
Cells were plated at a density of between 4105 and 2105
cells/ml of culture medium. Live cell concentrations were mea-
sured at speciﬁed intervals with a haemocytometer. Cells stained
with trypan blue (with a 1:10 dilution of 0.3% trypan blue
dissolved in phosphate-buffered saline [PBS]) or exhibiting aber-
rant morphologies were considered nonviable. After counting,
when necessary, cells were diluted in fresh medium back to their
approximate starting concentration.
Fig. 1. Netropsin increases the rate of loss of EBV plasmids from 293 cells in an EBNA1 AT-hook dependent manner. (A) Netropsin increases the rate of loss of EBV plasmids
from 293 cells. 293 cells harboring recombinant EBV plasmid (p2089) were cultured in the absence of Hygromycin and with either no netropsin (white bar) or 10 μM
netropsin (gray bar) for 18 days. The number of EBV genomes/cell was determined using qRT-PCR and the reduction in the number of viral genomes per cell after 18
days7netropsin is shown as % plasmid lost. (B) Culturing 293 cells with 10 μM netropsin does not affect their growth rate. 293 cells harboring 2089 were cultured as in (A).
Live cells were counted using a Trypan Blue exclusion assay and the number of doublings over 18 days was calculated. (C) Fusion proteins were made with the C-terminal
portion of EBNA1 (aa 376–641) and either the ﬁrst 22 amino acids of the KSHV LANA1 protein or the cellular histone H1 protein. The EBNA1 C-terminal domain used retained
the native Nuclear Localization Signal (NLS) and the DNA-Binding and dimerization Domain (DBD). The peptides were linked using a (GGGGSx2) linker. (D) EBV-derivative
plasmids can be maintained in 293 cells expressing the C-terminal portion of EBNA1 fused to either histone H1 (green bar) or the ﬁrst 22 amino acids of the KSHV LANA1
protein (maroon bar). “Wt EBNA1” refers to the parental p294-wtEBNA1 plasmid. (E) Netropsin increases the rate of loss of EBV-derived plasmids from 293 cells expressing
wt-EBNA1 (blue bars) but not from cells expressing LANA1- or H1- fusions with the C-terminal domain of EBNA1. 293 cells expressing wt-EBNA1, H1-EBNA1 (green bars) or
LANA1-EBNA1 (maroon bars) and harboring EBV-derived plasmids were grown with or without 10 μM netropsin for 18 days. The average number of EBV plasmids was
determined at day 18 using qRT-PCR and the reduction in the number of viral genomes per cell after 18 days7netropsin is shown as % plasmid lost. For all ﬁgures the
average of at least three independent trials is presented and the error bars show standard deviations [n¼po0.05].
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Fluorescence in situ hybridization
EBV-positive OkuI, SalI or JSC-1 Cells were prepared as
described and hybridized with probes that were generated as
described (Nanbo et al., 2007). At least 40 cells were counted per
replicate for each FISH assay.
DNA extraction and quantitative RT-PCR (qPCR)
DNAwas extracted using DNeasy Blood and Tissue Kit (Qiagen).
Real-time PCR was carried out as previously described (Vereide
and Sugden, 2011).
Statistics
Statistical analyses were performed using either Microsoft Excel or
MStat software, version 5.5 (N Drinkwater, McArdle Laboratory for
Cancer Research, School of Medicine and Public Health, University of
Wisconsin) and is available for downloading at: http://www.mcardle.
wisc.edu/mstat. At least three biological replicates and the Student's t-
test were used for statistical analyses unless otherwise stated.
Results
Netropsin increases the rate of loss of EBV plasmids from 293 cells in
an EBNA1 AT-hook dependent manner
If netropsin inhibits the ability of EBNA1's AT-hooks to bind
DNA and tether EBV genomes to cellular chromosomes in latently
infected cells we would expect to see loss of the viral DNAs from
those cells, as tethering has been shown to be necessary for the
replication and partitioning of viral plasmids (Kanda et al., 2001;
Holdin et al., 2013). But latently infected cells, including tumor
cells, depend on EBV for growth and survival, and those cells that
lose viral genomes die by apoptosis (Vereide and Sugden, 2011;
Kennedy et al., 2003). Therefore, it would be difﬁcult, if not
impossible, to measure accurately loss of EBV genomes from these
cells. To overcome this obstacle we developed an approach using
cells that are conditionally dependent on EBV DNA for growth and
survival.
We used 293 cells which harbor a recombinant version of EBV
called p2089, which comprises the B95.8 EBV genome and expresses
GFP and a gene encoding resistance to hygromycin (Delecluse et al.,
1998). When 293_p2089 cells are cultured in the presence of hygro-
mycin, p2089 persists in them, but in the absence of hygromycin these
cells are not dependent on p2089 for survival or growth and the
plasmids are lost over time as a result of defects in their synthesis
(Nanbo et al., 2007). We cultured 293_p2089 cells either in the
presence or absence of netropsin, but the absence of hygromycin, for
18 days (approximately 20 cell generations), to test whether netropsin
would increase the rate of loss of p2089. We extracted DNA after 18
days and determined the average number of p2089 plasmids/cell
using quantitative PCR (q-PCR).
Culturing 293_p2089 cells in the presence of 10 μM netropsin
increases the rate of loss of p2089 plasmids (Fig. 1A) without having
any inhibitory effect on the growth or viability of these cells (Fig. 1B,
Supplementary Fig. 1A). We did not use concentrations of netropsin
greater than 10 μM because at those higher concentrations the
293_2089 cells showed both slower growth and death as measured
by Trypan Blue exclusion assays (data not shown).
To conﬁrm that netropsin was speciﬁcally affecting the AT-hook
activity of EBNA1 in the cells we tested, we replaced the N-terminal
portion of EBNA1, which contains the AT-hook DNA-binding domains,
with either the histone H1protein or the ﬁrst 22 amino acids of the
LANA1 protein from Kaposi's Sarcoma-associated Herpes Virus
(KSHV). KSHV genomes appear to be tethered to cellular DNA through
attachments to Histone H2A and H2B mediated by LANA1, a viral
protein (Barbera et al., 2006, Shinohara et al., 2002). We generated
plasmids encoding these fusion proteins (p4880-H1 and p4881-LANA1
(1–22) respectively), the OriP portion of the EBV genome and a gene
encoding resistance to hygromycin (Fig. 1C). Both the H1/EBNA1-DBD
and the LANA1:1–22/EBNA1-DBD fusion proteins lack any AT-hook
DNA-binding domain, but we conﬁrmed previous results showing that
both are able to maintain EBV-derived plasmids in 293 cells in the
presence of selection, as are 293 cells harboring the parental p294-
wtEBNA1 (Fig. 1D) (Holdin et al., 2013; Hung et al., 2001).
We cultured 293 cells selected to harbor p294-wtEBNA1, p4880-H1
or p4881-LANA1 in the absence of hygromycin and in the presence or
absence of 10 μM netropsin for 18 days. We hypothesized that
netropsin would increase the rate of loss of p294-wtEBNA1 but not
that of p4880-H1 or p4881-LANA1 from these 293 cells as, unlike wt
EBNA1 with AT-hook binding domains, the fusion proteins are not
expected speciﬁcally to interact with AT-rich DNA. Cells were collected
after 18 days, DNA was extracted and the average number of p294-
wtEBNA1, p4880-H1 or p4881-LANA1 per cell was determined using
q-PCR. Unlike plasmids in 293 cells expressing wild-type EBNA, which
showed increased rates of loss in the presence of netropsin, the rate of
loss of p4880-H1 and p4881-LANA1 plasmids, although different from
each other, did not increase when the cells maintaining these plasmids
were cultured in the presence of 10 μM netropsin (Fig. 1E). In addition
the loss of the EBV-derived plasmids in the absence of selection
conﬁrmed the extrachromosomal nature of these DNAs.
Netropsin forces the loss of EBV, but not KSHV, genomes from dually-
infected PEL cells
Dually-infected primary effusion lymphomas (PELs) contain
both EBV and KSHV genomes as plasmids (Nador et al., 1996).
We tested whether culturing PELs in the presence of netropsin
would induce the loss of either EBV or KSHV genomes from these
tumor cells. Since KSHV genomes are not tethered to cellular DNA
via AT-hooks we predicted that netropsin would force the loss of
EBV but not KSHV genomes from dually-infected PEL cells.
We cultured JSC-1 PEL cells in the presence of 10 μM of
netropsin for 18 days. At this concentration, netropsin did not
have an adverse effect on the doubling time of these cells (Fig. 2A),
and neither did we see an increase in the number of dead or dying
cells using Trypan Blue exclusion assays (Supplementary Fig. 1 A).
Cells cultured in netropsin were collected after 18 days and the
numbers of EBV and KSHV genomes/cell were determined by FISH
(EBV) and/or qPCR (EBV and KSHV). Because JSC-1 cells contain
more than 100 copies of KSHV genomes per cell, we used qPCR to
assay the number of KSHV genomes. We found no signiﬁcant
difference between using FISH and qPCR to follow the loss of viral
genomes in the presence of netropsin (Supplementary Fig. 1B and
1C).
Netropsin caused a signiﬁcant loss of EBV plasmids in JSC-1
cells but did not decrease the number of KSHV genomes/cell in
JSC-1 cells (Fig. 2B), showing that its effect is speciﬁc to EBV and
EBNA1. These results were replicated using dually-infected BC-1
PEL cells (Fig. 2C and D).
Netropsin inhibits the growth of EBV-positive Wp-restricted BL cells
signiﬁcantly more than that of EBV-negative BL cells
Having established that netropsin can increase the rate of or
induce the loss of EBV genomes from different cell lines, we next
tested whether culturing tumor cell lines dependent on EBV for
survival in the presence of netropsin would A) lead to a decrease in
the average number of EBV genomes/cell and, as would be
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expected, B) inhibit their growth concomitant with this loss of
viral genomes.
We have shown that forcing the loss of EBV genomes from Wp-
restricted BL cells causes them to die by apoptosis (Vereide and
Sugden, 2011). When we cultured OkuI BL cells in the presence of
various amounts of netropsin we observed, as expected, a dose-
dependent decrease in the number of live cells over time
(Supplementary Fig. 2). We have also shown that exogenous
expression of the cellular anti-apoptotic protein Bcl-XL allows
Wp-restricted BL cells that have lost EBV to survive and continue
to proliferate (Vereide and Sugden, 2011). Therefore, we followed
the loss of viral genomes from Wp-restricted BL cells expressing
Bcl-XL to avoid the ambiguities resulting from analyzing dead and
dying cells. We cultured EBV-positive SalI-BL cells that exogenously
express Bcl-XL in the presence of 50 μM netropsin for 15 days. We
used 50 μM netropsin as this is the lowest concentration of
netropsin tested at which there is a continuous inhibition of growth
of parental Wp-restricted BL cells (Supplementary Fig. 2A). Cells
were counted every three days and live/dead cells were differen-
tiated using Trypan Blue staining. After 15 days, cells were collected
and the number of EBV genomes/cell was determined using FISH.
SalIþBcl-XL cells cultured with netropsin for 15 days had a
signiﬁcant decrease in the number of genomes per cell compared
to SalIþBcl-XL cells cultured in the absence of netropsin (Fig. 3A).
There was also a shift in the distribution of plasmids/cell and a
signiﬁcant increase in the percentage of cells with no EBV signal
(Fig. 3B). These experiments were replicated with OkuIþBcl-XL BL
cells (Fig. 3C and 3D).
Previous research (Vereide and Sugden, 2011), (Vereide et al., 2014)
has shown that while expression of Bcl-XL protects cells from
apoptosis upon loss of EBV genomes, the rate of proliferation of these
newly EBV-negative cells is decreased signiﬁcantly. Therefore culturing
EBV-positive SalIþBcl-XL cells in the presence of netropsin should
inhibit their growth concomitant with the observed loss of viral
genomes. Conversely, EBV-negative SalIþBcl-XL cells, which already
have a slower growth rate due to loss of EBV genomes should not be
affected by the presence of netropsin.
Netropsin signiﬁcantly inhibited the growth of EBV-positive
SalIþBcl-XL cells. The growth of EBV-negative SalIþBcl-XL cells
was also inhibited by netropsin but to a signiﬁcantly lesser extent
than that of the EBV-positive SalIþBcl-XL cells (Fig. 3E). We
conclude, therefore, that at least part of the decrease in the growth
Fig. 2. Netropsin forces the loss of EBV but not KSHV genomes from dually infected Primary Effusion Lymphoma cells. (A) Culturing JSC-1 cells with 10 μM netropsin does not
affect their growth rate. JSC-1 cells were cultured in the absence of netropsin (white bar) or 10 μM netropsin (gray bar) for 18 days. Live cells were counted using a Trypan
Blue exclusion assay and the number of doublings over 18 days was calculated. (B) Netropsin forces the loss of EBV, but not KSHV, genomes from JSC-1 cells. Dually-positive
JSC-1 cells were cultured as in (A). The number of EBV (blue triangles) and KSHV (red squares) genomes per cell was determined using FISH or qRT-PCR. The reduction in the
number of viral genomes in cells cultured in the presence of netropsin compared to number of genomes in cells cultured without netropsin was calculated as % plasmid lost.
At least 80 cells were counted per replicate. (C), (D) These results were replicated for BC-1 cells. For all ﬁgures the average of at least three independent experiments is
shown. Error bars show standard deviations.
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Fig. 3. Netropsin forces the loss of EBV genomes from Wp-restricted Burkitt's Lymphoma cells and inhibits their growth. (A) Netropsin forces the loss of EBV plasmids from
SalI BL cells. EBV-positive SalI cells were cultured with either no netropsin (white bar) or 50uM netropsin (blue bar) for 15 days. The number of EBV genomes per cell was
determined using FISH. The average of three independent experiments is presented with error bars showing standard deviations [*¼po0.05]. (B) Culturing SalI BL cells with
netropsin changes the distribution of EBV genomes/cell and increases the percentage of cells with no EBV genomes. SalI cells were cultured with and without netropsin as in
(A) and the distribution of EBV genomes in cells7netropsin was determined using FISH. The distribution of cells with different number of EBV genomes is presented as a
percentage of the total number of cells counted (n¼120). (C), (D) These results were replicated with OkuI-BL cells with experiments over 7 days. (E) Netropsin inhibits the
growth of EBV-positive SalI BL cells signiﬁcantly more than that of EBV-negative SalI BL cells. EBV-positive (white bar) and EBV-negative (blue bar) SalIþBcl-XL BL cells were
grown as in (A). Live cells were counted every 3 days using a haemocytometer and Trypan Blue exclusion assay. Cumulative doublings were calculated for EBV7SalI BL cells
grown7netropsin. The number of doublings at each time point for SalI BL cells grown in the presence of netropsin was normalized to the number of doublings by cells
grown in the absence of netropsin. In the absence of netropsin doublings times did not change over the duration of the experiment. The average of three independent
experiments is presented. Error bars show standard deviations [ *¼po0.05].
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rate of EBV-positive SalIþBcl-XL cells in the presence of netropsin
results from the induced loss of EBV genomes.
Discussion
EBV DNA persists in latently infected cells, including tumor
cells, as extrachromosomal plasmids. The replication of these
plasmids during the S-phase of the cell cycle and their subsequent
partitioning to daughter cells during mitosis and cell division
requires them being tethered to cellular chromosomes (Kanda
et al., 2001; Holdin et al., 2013; Sears et al., 2004b)].
Two domains in the N-terminal portion of the EBV protein
EBNA1—LR1 and LR2—have been shown to play a crucial role in
mediating the association of viral genomes to cellular DNA (Sears
et al., 2004a, 2004b; Norseen et al., 2009; Wu et al., 2002). But the
mechanism by which these two domains mediate tethering of EBV
genomes to cellular chromosomes has been unclear because LR1
and LR2 have been shown to have multiple functions including
interacting with DNA, RNA, and cellular proteins.
We reasoned that we could use the small molecule netropsin,
which binds to the minor groove of AT-rich DNA and inhibits LR1
and LR2 binding to poly-dA.dT DNA in vitro (Sears et al., 2004b), to
inhibit speciﬁcally the AT-hook binding of EBNA1's LR1 and LR2 to
AT-rich DNA in vivo without impinging on its ability to interact
with G-rich RNAs (Norseen et al., 2009) or other cellular proteins
(Shire et al., 1999; Jourdan et al., 2012).
By culturing cells that maintain recombinant EBV genomes
with netropsin we showed that speciﬁcally inhibiting the AT-hook
binding ability of EBNA1 increases the rate of loss of the recombi-
nant EBV genomes from these cells. This increased loss of viral
genomes occurred without affecting the growth of epithelial (293)
and lymphoid (JSC-1 and BC-1) cells showing that this loss of EBV
DNA is unrelated to the cytotoxic effects seen with netropsin when
used at higher concentrations.
Netropsin does not increase the rate of loss of EBV derivatives
when the AT-hook domains of EBNA1 are replaced by H1 or the N-
terminal 22 amino acids of KSHV LANA1 or force the loss of KSHV
genomes from dually-infected PEL cells. The induced loss of EBV
replicons by netropsin depends on EBNA1's AT-hooks, which
conﬁrms the hypothesis that the AT-hook DNA-binding ability of
EBNA1 LR1 and LR2 is necessary for the maintenance of EBV
genomes in latently infected cells.
Interestingly, we and others have shown that the entire
N-terminal half of EBNA1 can be replaced by proteins with or
without AT-hook DNA-binding domains that maintain EBV-
derived plasmids (Holdin et al., 2013; Sears et al., 2004b; Hung
et al., 2001).These seemingly contradictory ﬁndings together
indicate an EBNA1-fusion protein must be able to bind mitotic
chromosomes by some means in order to maintain EBV-derived
plasmids in cells.
Culturing Wp-restricted BL cells in the presence of netropsin
caused a signiﬁcant decrease in the average number of EBV genomes
per cell and increased the proportion of cells with no EBV genomes.
This loss of EBV genomes in the presence of netropsin signiﬁcantly
inhibited the growth of these EBV-positive BL cell lines expressing
Bcl-XL. While netropsin also inhibited the growth of EBV-negative
Wp-restricted BL cells, likely due to interfering with ORC binding to
AT-rich cellular sequences (Vashee et al., 2003), we found that
netropsin inhibits the growth of EBV-positive BL cells signiﬁcantly
more than that of the EBV-negative cells.
EBV is linked to several human malignancies and inhibiting
functions of the viral protein EBNA1 is a compelling potential
treatment for these cancers (Sun et al., 2010; Kang et al., 2012;
Thompson et al., 2010; Jiang et al., 2014). Small molecules that
inhibit the binding of EBNA1's AT-hooks to cellular DNA, and
thereby force its loss from cells, have potential as therapies against
EBV-related malignancies because EBV has been shown to be
required to maintain these tumors (Vereide and Sugden 2011;
Kennedy et al., 2003). Netropsin is too toxic to use in patients, but
our results indicate molecules that directly bind the AT-hook
domains of EBNA1 should force the loss of EBV genomes from
tumor cells and be therapeutically beneﬁcial.
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